Literature DB >> 26072255

Patient Cases 2. A Patient with Apparent Resistant Hypertension.

Carlos Aguiar1.   

Abstract

True treatment-resistant hypertension (TRH) is defined by specific criteria and a failure to response to initial therapy options does not necessarily mean that a patient has TRH. In this case, a 44-year-old male was discharged on a fixed combination of valsartan/hydrochlorothiazide (HCTZ) 160/125 mg/day after presenting to the emergency room with paraesthesia of the upper left limb and recording a blood pressure (BP) of 190/110 mmHg. The patient had a number of other cardiovascular (CV) risk factors, and was determined to be at high risk of developing type 2 diabetes mellitus and of CV death. Carvedilol and atorvastatin were added, but 24-h ambulatory BP monitoring (ABPM) showed persistent hypertension. After specialist assessment, the patient's antihypertensive regimen was switched to a fixed-dose combination of olmesartan/HCTZ in the morning and a fixed-dose combination of olmesartan/amlodipine in the evening. Repeat ABPM 6 weeks later showed better BP control then previous ABPM.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26072255     DOI: 10.1007/s40292-015-0111-6

Source DB:  PubMed          Journal:  High Blood Press Cardiovasc Prev        ISSN: 1120-9879


  10 in total

Review 1.  A systematic review and meta-analysis on the therapeutic equivalence of statins.

Authors:  T-C Weng; Y-H Kao Yang; S-J Lin; S-H Tai
Journal:  J Clin Pharm Ther       Date:  2010-04       Impact factor: 2.512

2.  ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD).

Authors:  Lars Rydén; Peter J Grant; Stefan D Anker; Christian Berne; Francesco Cosentino; Nicolas Danchin; Christi Deaton; Javier Escaned; Hans-Peter Hammes; Heikki Huikuri; Michel Marre; Nikolaus Marx; Linda Mellbin; Jan Ostergren; Carlo Patrono; Petar Seferovic; Miguel Sousa Uva; Marja-Riita Taskinen; Michal Tendera; Jaakko Tuomilehto; Paul Valensi; Jose Luis Zamorano; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Guy De Backer; Per Anton Sirnes; Eduardo Alegria Ezquerra; Angelo Avogaro; Lina Badimon; Elena Baranova; Helmut Baumgartner; John Betteridge; Antonio Ceriello; Robert Fagard; Christian Funck-Brentano; Dietrich C Gulba; David Hasdai; Arno W Hoes; John K Kjekshus; Juhani Knuuti; Philippe Kolh; Eli Lev; Christian Mueller; Ludwig Neyses; Peter M Nilsson; Joep Perk; Piotr Ponikowski; Zeljko Reiner; Naveed Sattar; Volker Schächinger; André Scheen; Henrik Schirmer; Anna Strömberg; Svetlana Sudzhaeva; Juan Luis Tamargo; Margus Viigimaa; Charalambos Vlachopoulos; Robert G Xuereb
Journal:  Eur Heart J       Date:  2013-08-30       Impact factor: 29.983

3.  European Society of Hypertension position paper on ambulatory blood pressure monitoring.

Authors:  Eoin O'Brien; Gianfranco Parati; George Stergiou; Roland Asmar; Laurie Beilin; Grzegorz Bilo; Denis Clement; Alejandro de la Sierra; Peter de Leeuw; Eamon Dolan; Robert Fagard; John Graves; Geoffrey A Head; Yutaka Imai; Kazuomi Kario; Empar Lurbe; Jean-Michel Mallion; Giuseppe Mancia; Thomas Mengden; Martin Myers; Gbenga Ogedegbe; Takayoshi Ohkubo; Stefano Omboni; Paolo Palatini; Josep Redon; Luis M Ruilope; Andrew Shennan; Jan A Staessen; Gert vanMontfrans; Paolo Verdecchia; Bernard Waeber; Jiguang Wang; Alberto Zanchetti; Yuqing Zhang
Journal:  J Hypertens       Date:  2013-09       Impact factor: 4.844

4.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors:  Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

5.  Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis.

Authors:  Dharam J Kumbhani; P Gabriel Steg; Christopher P Cannon; Kim A Eagle; Sidney C Smith; Kevin Crowley; Shinya Goto; E Magnus Ohman; George L Bakris; Todd S Perlstein; Scott Kinlay; Deepak L Bhatt
Journal:  Eur Heart J       Date:  2012-11-09       Impact factor: 29.983

Review 6.  Pitavastatin.

Authors:  R Y A Mukhtar; J Reid; J P D Reckless
Journal:  Int J Clin Pract       Date:  2005-02       Impact factor: 2.503

Review 7.  Apparent and true resistant hypertension: definition, prevalence and outcomes.

Authors:  E Judd; D A Calhoun
Journal:  J Hum Hypertens       Date:  2014-01-16       Impact factor: 3.012

8.  2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redón; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad
Journal:  J Hypertens       Date:  2013-07       Impact factor: 4.844

9.  A medication adherence and persistence comparison of hypertensive patients treated with single-, double- and triple-pill combination therapy.

Authors:  Lin Xie; Feride Frech-Tamas; Elizabeth Marrett; Onur Baser
Journal:  Curr Med Res Opin       Date:  2014-09-29       Impact factor: 2.580

10.  European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).

Authors:  Joep Perk; Guy De Backer; Helmut Gohlke; Ian Graham; Zeljko Reiner; Monique Verschuren; Christian Albus; Pascale Benlian; Gudrun Boysen; Renata Cifkova; Christi Deaton; Shah Ebrahim; Miles Fisher; Giuseppe Germano; Richard Hobbs; Arno Hoes; Sehnaz Karadeniz; Alessandro Mezzani; Eva Prescott; Lars Ryden; Martin Scherer; Mikko Syvänne; Wilma J M Scholte op Reimer; Christiaan Vrints; David Wood; Jose Luis Zamorano; Faiez Zannad
Journal:  Eur Heart J       Date:  2012-05-03       Impact factor: 29.983

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.